NEW YORK (GenomeWeb News) - ExonHit Therapeutics has granted Merck a license to its RNA splicing microarray patent, ExonHit said yesterday.
 
The non-exclusive license gives rights to the patent -- US No. 6,881,571, titled “Qualitative Differential Screening” -- for research use only. The patent has claims directed to microarrays optimized to monitor RNA splicing events, the company said.
 
ExonHit does not expect to receive more than $150,000 in revenues per year under this agreement.
 

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

A new analysis examines the gender gap among paper authors in the sciences and says it may take decades or more to close.

Researchers have uncovered signals of selection that may enable the Bajau people to free five hundreds of feet deep, Reuters reports.

In Science this week: paternally inherited cis-regulatory structural variants in autism, and more.

A new report outlines issues facing the implementation of personalized medicine in the UK, the Independent reports.

May
01
Sponsored by
Horizon Discovery

This webinar will provide an in-depth case study demonstrating how reference standards can be used to develop and validate circulating tumor DNA (ctDNA)-based assays.

May
08
Sponsored by
Dovetail Genomics

This webinar will discuss a proximity ligation-based method for studying structural variation in formalin-fixed paraffin-embedded (FFPE) tissue.